Ceremorphic announced the formation of a new life sciences division called 'Ceremorphic Life Sciences,' which has been established to transform the entire drug discovery and development process.

The new division will have access to Ceremorphic’s own proprietary analog and AI technology platform that will allow its team of biology and chemistry experts to begin developing drugs at a pace unprecedented in the pharmaceutical industry.

With more than 10,000 diseases in the world and only 500 drugs available today, the Ceremorphic Life Sciences platform is the first solution capable of closing that gap by bringing efficiency at each level of the current design pipeline. Recent innovations on novel algorithms, hardware and AI technology advancements have enabled computer sciences and AI to play a critical role in designing a drug in addition to traditional expertise in biology and chemistry. Ceremorphic’s life sciences division leverages its over 5,000 person-year expertise of hardware, algorithms and AI to make this new architecture a reality.

“One new drug today typically requires over 10 years to develop, which can easily cost a pharma company more than USD 2 billion to bring to market,” said Dr. Venkat Mattela, Founder and CEO of Ceremorphic.” In addition to the cost, the drug development throughput and the balance of safety and efficacy is sub-optimal. This is going to change with Ceremorphic Life Sciences new design methodology because we have developed a new platform that can speed every single phase of discovery and development and selectivity at every stage. This type of platform has been long considered the holy grail of drug development and we are making it a reality that can transform the entire pharmaceutical industry for the benefit of all of society.”

Dr. William Haseltine, former Professor at Harvard Medical School and Founder Chairman and CEO of Human Genome Sciences (HGS) also stated "Current In Silico methods using the wet labs have limitations on scalability to produce enough data to use AI effectively. Ceremorphic’s hybrid approach utilizing analog circuit technology is unique. This approach not only accelerates computation speed, but also empowers AI to be highly effective throughout the entire development process.”